10-Q: Renalytix Reports Q2 2024 Results, Faces Nasdaq Compliance Challenges Amidst Cost-Cutting Efforts

Renalytix reports a decrease in revenue and increased net losses for the second quarter of fiscal year 2024, while also addressing Nasdaq compliance issues and implementing cost reduction measures.

Summary

• Renalytix reported a revenue of $709,000 for the three months ended December 31, 2023, a decrease from $1.2 million in the same period of 2022.
• The company's net loss for the quarter was $8.5 million, compared to a net loss of $10.4 million in the prior year.
• For the six months ended December 31, 2023, revenue was $1.2 million, down from $2.2 million in 2022, and the net loss was $18.6 million, compared to $22.4 million in 2022.
• The company is facing challenges to maintain its listing on the Nasdaq Global Market due to its share price falling below $1.00 and a market value of listed securities below $50 million.
• Renalytix is implementing cost reduction measures, targeting a 33% reduction in cash burn for the fiscal third quarter compared to the prior quarter and a 50% reduction compared to the first quarter of fiscal 2024.
• The company's cash and cash equivalents stood at $5.6 million as of December 31, 2023, and it anticipates needing additional capital to fund operations.
• There is substantial doubt about the company's ability to continue as a going concern within the next 12 months.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with declining revenue, significant losses, and concerns about the company's ability to continue as a going concern. While there are some positive developments, such as the inclusion of KidneyIntelX in the CMS fee schedule, the overall sentiment is negative due to the financial and operational risks.

Positives

• The net loss decreased for both the three and six month periods ended December 31, 2023 compared to the same periods in 2022.
• Operating cost reductions have commenced and are expected to continue.
• KidneyIntelX is included in the lab fee schedule by CMS at $950 per test.
• Real-world evidence supports the clinical benefits of KidneyIntelX.

Negatives

• Revenue decreased for both the three and six month periods ended December 31, 2023 compared to the same periods in 2022.
• The company has incurred recurring losses and negative cash flows from operations since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is not in compliance with Nasdaq listing rules regarding minimum bid price and market value of listed securities.
• The company's cash reserves have significantly decreased.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting.
• The company faces risks associated with commercializing KidneyIntelX, including market acceptance and reimbursement.
• Macroeconomic conditions, including inflation and interest rate hikes, may negatively affect the company's growth.
• The company is subject to risks common to early-stage companies in the diagnostics industry, including competition and dependence on key personnel.

Future Outlook

The company anticipates incurring additional losses until it can generate significant sales of KidneyIntelX or future products. It plans to finance its cash needs through a combination of revenue from sales, securities offerings, debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements with third parties. The company expects its cash and cash equivalents, combined with cost reduction options, will be sufficient to fund operations into early fiscal fourth quarter.

Management Comments

• Management intends to continue its efforts to contain costs and to raise additional capital until we can generate sufficient cash from commercial sales to support operations, if ever.
• We intend to actively monitor our MVLS and the closing bid price of our ADS and may, if appropriate, implement available options to regain compliance with the MVLS Requirement and the Minimum Bid Price Requirement.

Industry Context

The company operates in the in-vitro diagnostics industry, focusing on kidney disease management. The inclusion of KidneyIntelX in the CMS lab fee schedule and proposed LCD by NGS are positive developments for market access. The company's focus on partnerships with healthcare systems and insurance payors aligns with industry trends towards value-based care and personalized medicine.

Comparison to Industry Standards

• The company's revenue of $1.2 million for the six months ended December 31, 2023, is low compared to established diagnostics companies, reflecting its early stage of commercialization.
• The net loss of $18.6 million for the same period indicates significant ongoing investment in research and development and commercialization efforts, which is typical for companies in this sector.
• The company's cash burn rate is a concern, and its ability to reduce costs and secure additional funding will be critical for its long-term viability.
• The inclusion of KidneyIntelX in the CMS lab fee schedule at $950 per test is a positive development, but the company needs to secure broader coverage and reimbursement from private payors to achieve significant revenue growth.
• The company's real-world evidence demonstrating a 61% increase in kidney protective drug prescriptions among high-risk patients after KidneyIntelX testing is a positive indicator of the clinical utility of its product, which is important for adoption by healthcare providers.

Corporate Governance

Related Party Transactions

• The company incurred expenses related to employees of EKF who provided services to Renalytix.
• The company has obligations under the ISMMS license agreement and amounts due to ISMMS are included within accrued expenses and other current liabilities and accounts payable on the balance sheet.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital and the risk of delisting from Nasdaq.
• Employees may be affected by cost reduction measures, including potential headcount reductions.
• Customers and healthcare providers may be impacted by the company's ability to continue operations and provide access to KidneyIntelX.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company intends to actively monitor its MVLS and the closing bid price of its ADS and may, if appropriate, implement available options to regain compliance with the MVLS Requirement and the Minimum Bid Price Requirement.
• The company plans to continue its efforts to contain costs and to raise additional capital.
• The company will continue to pursue Medicare coverage and a determination under the MolDX Program.
• The company will continue to work with additional private insurance payors and healthcare providers to expand insurance coverage for KidneyIntelX nationwide.

Key Dates

Keywords

Renalytix, KidneyIntelX, Chronic Kidney Disease, Diagnostics, Nasdaq, Financial Results, Cost Reduction, Medicare, Going Concern, Liquidity